PriceTargets.com logo

Quest Diagnostics - DGX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $196.31
  • Forecasted Upside: 6.54%
  • Number of Analysts: 19
  • Breakdown:
  • 0 Sell Ratings
  • 10 Hold Ratings
  • 8 Buy Ratings
  • 1 Strong Buy Ratings
$184.27 As of 12/4/2025 04:59 PM ET
▲ +1.657 (0.91%)

This chart shows the closing price for DGX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Quest Diagnostics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DGX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DGX

Analyst Price Target is $196.31
▲ +6.54% Upside Potential
This price target is based on 19 analysts offering 12 month price targets for Quest Diagnostics in the last 3 months. The average price target is $196.31, with a high forecast of $215.00 and a low forecast of $178.00. The average price target represents a 6.54% upside from the last price of $184.27.

This chart shows the closing price for DGX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 19 contributing investment analysts is to moderate buy stock in Quest Diagnostics. This rating has held steady since October 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 9 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 2 strong buy ratings
  • 6 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 2 strong buy ratings
  • 7 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 1 strong buy ratings
  • 7 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 1 strong buy ratings
  • 8 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2025
  • 1 strong buy ratings
  • 8 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 1 strong buy ratings
  • 8 buy ratings
  • 10 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/27/2025Piper SandlerBoost TargetNeutral ➝ Neutral$190.00 ➝ $200.00
10/22/2025Truist FinancialBoost TargetHold ➝ Hold$195.00 ➝ $205.00
10/22/2025Morgan StanleySet TargetOverweight ➝ Overweight$207.00
10/22/2025BarclaysBoost TargetEqual Weight ➝ Equal Weight$190.00 ➝ $195.00
10/21/2025Jefferies Financial GroupBoost TargetBuy ➝ Buy$200.00 ➝ $215.00
10/21/2025Leerink PartnersBoost TargetOutperform ➝ Outperform$203.00 ➝ $210.00
10/21/2025Leerink PartnersBoost TargetOutperform ➝ Outperform$203.00 ➝ $210.00
10/17/2025UBS GroupBoost TargetNeutral ➝ Neutral$180.00 ➝ $190.00
10/17/2025MizuhoBoost TargetOutperform ➝ Outperform$190.00 ➝ $210.00
10/14/2025Truist FinancialSet Target$195.00
10/8/2025Weiss RatingsReiterated RatingBuy (B) ➝ Buy (B)
10/8/2025Evercore ISIBoost TargetIn-Line ➝ In-Line$185.00 ➝ $190.00
10/2/2025BarclaysBoost TargetEqual Weight ➝ Equal Weight$185.00 ➝ $190.00
9/27/2025Weiss RatingsReiterated RatingBuy (B) ➝ Buy (B)
8/25/2025Baird R WDowngradeStrong-Buy ➝ Hold
8/25/2025Robert W. BairdReiterated RatingOutperform ➝ Neutral$194.00
7/23/2025Evercore ISISet Target$185.00
7/23/2025William BlairReiterated RatingOutperform
7/23/2025Truist FinancialBoost TargetHold ➝ Hold$190.00 ➝ $192.00
7/23/2025Deutsche Bank AktiengesellschaftBoost TargetHold ➝ Hold$160.00 ➝ $178.00
7/18/2025UBS GroupLower TargetNeutral ➝ Neutral$176.00 ➝ $175.00
5/6/2025JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$180.00 ➝ $190.00
4/28/2025Piper SandlerBoost TargetNeutral ➝ Neutral$180.00 ➝ $200.00
4/23/2025Truist FinancialBoost TargetHold ➝ Hold$182.00 ➝ $190.00
4/23/2025Evercore ISIBoost TargetIn-Line ➝ In-Line$175.00 ➝ $180.00
4/23/2025BarclaysBoost TargetEqual Weight ➝ Equal Weight$175.00 ➝ $185.00
4/23/2025Robert W. BairdBoost TargetOutperform ➝ Outperform$191.00 ➝ $194.00
4/9/2025MizuhoBoost TargetOutperform ➝ Outperform$178.00 ➝ $189.00
4/2/2025Redburn PartnersSet Target$195.00
4/2/2025Redburn AtlanticInitiated CoverageBuy$195.00
3/20/2025Robert W. BairdBoost TargetOutperform ➝ Outperform$190.00 ➝ $191.00
3/4/2025CitigroupDowngradeBuy ➝ Neutral$185.00 ➝ $185.00
2/4/2025JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$173.00 ➝ $180.00
2/3/2025MizuhoBoost TargetOutperform ➝ Outperform$177.00 ➝ $178.00
2/3/2025UBS GroupBoost TargetNeutral ➝ Neutral$166.00 ➝ $170.00
2/3/2025Piper SandlerReiterated RatingNeutral ➝ Neutral$165.00 ➝ $180.00
1/31/2025Robert W. BairdSet Target$189.00
1/31/2025Truist FinancialBoost TargetHold ➝ Hold$172.00 ➝ $182.00
1/31/2025BarclaysBoost TargetEqual Weight ➝ Equal Weight$168.00 ➝ $175.00
1/6/2025Leerink PartnrsUpgradeHold ➝ Strong-Buy
1/6/2025Leerink PartnersUpgradeMarket Perform ➝ Outperform$169.00 ➝ $174.00
12/17/2024Morgan StanleyUpgradeEqual Weight ➝ Overweight$145.00 ➝ $172.00
12/13/2024Bank of AmericaBoost TargetBuy ➝ Buy$179.00 ➝ $182.00
12/10/2024Jefferies Financial GroupReiterated RatingBuy ➝ Buy$175.00 ➝ $185.00
10/28/2024Piper SandlerBoost TargetNeutral ➝ Neutral$150.00 ➝ $165.00
10/24/2024MizuhoBoost TargetOutperform ➝ Outperform$160.00 ➝ $174.00
10/23/2024Baird R WUpgradeHold ➝ Strong-Buy
10/23/2024UBS GroupBoost TargetNeutral ➝ Neutral$165.00 ➝ $166.00
10/23/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$154.00 ➝ $168.00
10/23/2024CitigroupBoost TargetBuy ➝ Buy$165.00 ➝ $185.00
10/23/2024Robert W. BairdUpgradeNeutral ➝ Outperform$157.00 ➝ $182.00
10/7/2024Truist FinancialBoost TargetHold ➝ Hold$158.00 ➝ $165.00
8/28/2024Evercore ISIInitiated CoverageIn-Line$165.00
8/27/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$144.00 ➝ $154.00
7/29/2024Piper SandlerBoost TargetNeutral ➝ Neutral$145.00 ➝ $150.00
7/24/2024Robert W. BairdBoost TargetNeutral ➝ Neutral$153.00 ➝ $154.00
7/15/2024Truist FinancialBoost TargetHold ➝ Hold$150.00 ➝ $158.00
7/10/2024CitigroupUpgradeNeutral ➝ Buy$145.00 ➝ $165.00
7/5/2024Robert W. BairdBoost TargetNeutral ➝ Neutral$145.00 ➝ $153.00
5/30/2024JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$152.00 ➝ $155.00
4/25/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$138.00 ➝ $144.00
4/24/2024CitigroupBoost TargetNeutral ➝ Neutral$135.00 ➝ $145.00
4/24/2024UBS GroupBoost TargetNeutral ➝ Neutral$139.00 ➝ $146.00
4/24/2024Truist FinancialBoost TargetHold ➝ Hold$145.00 ➝ $150.00
4/24/2024MizuhoBoost TargetBuy ➝ Buy$150.00 ➝ $155.00
3/20/2024Truist FinancialReiterated RatingHold ➝ Hold$145.00
2/26/2024Leerink PartnrsReiterated RatingMarket Perform
2/26/2024Leerink PartnersInitiated CoverageMarket Perform$135.00
2/7/2024Jefferies Financial GroupUpgradeHold ➝ Buy$140.00 ➝ $155.00
2/2/2024Truist FinancialLower TargetHold ➝ Hold$150.00 ➝ $145.00
1/3/2024BarclaysInitiated CoverageEqual Weight$145.00
12/20/2023Truist FinancialBoost TargetHold ➝ Hold$145.00 ➝ $150.00
12/12/2023Bank of AmericaUpgradeNeutral ➝ Buy$140.00 ➝ $160.00
12/11/2023CitigroupBoost TargetNeutral ➝ Neutral$130.00 ➝ $145.00
12/7/2023UBS GroupBoost TargetNeutral ➝ Neutral$135.00 ➝ $137.00
11/17/2023JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$148.00 ➝ $149.00
11/6/2023Piper SandlerBoost TargetNeutral ➝ Neutral$130.00 ➝ $140.00
10/25/2023CitigroupLower TargetNeutral ➝ Neutral$142.00 ➝ $130.00
10/16/2023Piper SandlerLower TargetNeutral ➝ Neutral$145.00 ➝ $130.00
10/11/2023Evercore ISILower Target$136.00 ➝ $130.00
8/3/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$145.00
6/29/2023Piper SandlerInitiated CoverageNeutral
5/2/2023Bank of AmericaDowngradeBuy ➝ Neutral$166.00 ➝ $148.00
4/3/2023CitigroupUpgradeSell ➝ Neutral$125.00 ➝ $142.00
3/17/2023MizuhoReiterated RatingBuy$165.00
3/17/2023Truist FinancialLower TargetHold$170.00 ➝ $160.00
2/3/2023Wells Fargo & CompanyBoost TargetEqual Weight$135.00 ➝ $140.00
1/25/2023Credit Suisse GroupBoost TargetNeutral$143.00 ➝ $146.00
1/23/2023Evercore ISIInitiated CoverageInline$159.00
1/12/2023Robert W. BairdBoost TargetNeutral$143.00 ➝ $154.00
1/6/2023Morgan StanleyBoost TargetEqual Weight$146.00 ➝ $158.00
12/14/2022MizuhoBoost TargetBuy$160.00 ➝ $165.00
11/17/2022CitigroupDowngradeNeutral ➝ Sell$145.00 ➝ $125.00
10/21/2022Morgan StanleyBoost TargetEqual Weight$142.00 ➝ $146.00
10/21/2022Deutsche Bank AktiengesellschaftBoost TargetHold$129.00 ➝ $140.00
10/20/2022William BlairReiterated RatingOutperform
8/22/2022Morgan StanleyReiterated RatingEqual Weight$142.00
4/25/2022Wells Fargo & CompanyBoost TargetEqual Weight$145.00 ➝ $150.00
4/24/2022UBS GroupBoost Target$139.00 ➝ $150.00
4/22/2022Bank of AmericaLower TargetBuy$166.00 ➝ $163.00
4/4/2022CitigroupDowngradeBuy ➝ Neutral$175.00 ➝ $140.00
2/23/2022UBS GroupDowngradeBuy ➝ Neutral$160.00 ➝ $139.00
2/14/2022Morgan StanleyLower TargetEqual Weight$159.00 ➝ $145.00
2/4/2022Wells Fargo & CompanyLower TargetEqual Weight$160.00 ➝ $145.00
2/4/2022Robert W. BairdLower Target$162.00 ➝ $146.00
2/2/2022Jefferies Financial GroupDowngradeBuy ➝ Hold$135.00
1/28/2022Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$190.00 ➝ $129.00
1/19/2022Truist FinancialLower Target$170.00 ➝ $160.00
1/13/2022Robert W. BairdLower Target$173.00 ➝ $162.00
1/10/2022Deutsche Bank AktiengesellschaftBoost Target$160.00 ➝ $190.00
1/5/2022Truist FinancialBoost Target$150.00 ➝ $170.00
12/17/2021Morgan StanleyLower TargetEqual Weight$165.00 ➝ $159.00
12/14/2021Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$150.00 ➝ $160.00
12/13/2021KeyCorpBoost TargetOverweight$168.00 ➝ $170.00
10/26/2021Wells Fargo & CompanyBoost TargetEqual Weight$140.00 ➝ $150.00
10/22/2021Deutsche Bank AktiengesellschaftBoost TargetBuy$150.00 ➝ $160.00
9/10/2021CitigroupBoost TargetBuy$158.00 ➝ $181.00
9/1/2021KeyCorpBoost TargetIn-Line ➝ Overweight$144.00 ➝ $168.00
8/31/2021Morgan StanleyBoost TargetEqual Weight$136.00 ➝ $165.00
8/19/2021MizuhoBoost TargetBuy$158.00 ➝ $166.00
8/13/2021Credit Suisse GroupBoost TargetNeutral$135.00 ➝ $150.00
7/23/2021Jefferies Financial GroupInitiated CoverageBuy$160.00
5/12/2021MizuhoBoost TargetBuy$149.00 ➝ $158.00
5/4/2021UBS GroupUpgradeNeutral ➝ Buy$135.00 ➝ $158.00
3/18/2021Robert W. BairdReiterated RatingOutperform ➝ Neutral$137.00
3/12/2021Morgan StanleyBoost TargetEqual Weight$130.00 ➝ $136.00
3/12/2021Robert W. BairdDowngradeOutperform ➝ Neutral$137.00
1/29/2021CitigroupBoost Target$151.00 ➝ $158.00
12/17/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight
(Data available from 12/4/2020 forward)

News Sentiment Rating

1.51 (Strong Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 45 very positive mentions
  • 28 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 82 very positive mentions
  • 25 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 60 very positive mentions
  • 21 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 64 very positive mentions
  • 35 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 86 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 86 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Quest Diagnostics logo
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Read More

Today's Range

Now: $184.27
Low: $182.25
High: $185.12

50 Day Range

MA: $184.07
Low: $174.90
High: $192.41

52 Week Range

Now: $184.27
Low: $148.70
High: $197.55

Volume

1,044,858 shs

Average Volume

1,125,294 shs

Market Capitalization

$20.50 billion

P/E Ratio

21.63

Dividend Yield

1.75%

Beta

0.62

Frequently Asked Questions

What sell-side analysts currently cover shares of Quest Diagnostics?

The following sell-side analysts have issued research reports on Quest Diagnostics in the last twelve months: Baird R W, Bank of America Corporation, Barclays PLC, Citigroup Inc., Deutsche Bank Aktiengesellschaft, Evercore ISI, Jefferies Financial Group Inc., JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Mizuho, Morgan Stanley, Piper Sandler, Redburn Atlantic, Redburn Partners, Robert W. Baird, Truist Financial Corporation, UBS Group AG, Wall Street Zen, Weiss Ratings, and William Blair.
View the latest analyst ratings for DGX.

What is the current price target for Quest Diagnostics?

0 Wall Street analysts have set twelve-month price targets for Quest Diagnostics in the last year. Their average twelve-month price target is $196.31, suggesting a possible upside of 6.5%. Jefferies Financial Group Inc. has the highest price target set, predicting DGX will reach $215.00 in the next twelve months. Deutsche Bank Aktiengesellschaft has the lowest price target set, forecasting a price of $178.00 for Quest Diagnostics in the next year.
View the latest price targets for DGX.

What is the current consensus analyst rating for Quest Diagnostics?

Quest Diagnostics currently has 10 hold ratings, 8 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for DGX.

What other companies compete with Quest Diagnostics?

Other companies that are similar to Quest Diagnostics include Henry Schein, Medpace, AMN Healthcare Services, Labcorp and DaVita. Learn More about companies similar to Quest Diagnostics.

How do I contact Quest Diagnostics' investor relations team?

Quest Diagnostics' physical mailing address is 500 PLAZA DRIVE, SECAUCUS NJ, 07094. The medical research company's listed phone number is (973) 520-2700 and its investor relations email address is [email protected]. The official website for Quest Diagnostics is www.questdiagnostics.com. Learn More about contacing Quest Diagnostics investor relations.